- Screener
- Securities US
- Pfizer Inc
Pfizer Inc
$22.10
-$0.11
-0.47%
21 Apr 20:00
$20.92
$31.54
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
weak bullish sentiment increases
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | ||
Support | ||
Cash flows |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
-0.81Sentiment
BearishStart Date
03.26.2025Duration
22Yield
-12.11%Avg.Yield
-7.80%
Volatility
1.58%Max MDD
-15.04%Avg. MDD
-10.81%Min Price
RUB 21.59Max Price
RUB 25.34
Protective stop levels
S/L 5%RUB 23.14 | S/L 10%RUB 24.24 | S/L 15%RUB 25.35 | |
|---|---|---|---|
Day | 0.51% | 0.00% | 0.00% |
Week | 21.02% | 1.02% | 0.01% |
Month | 54.09% | 20.98% | 6.18% |
Technical analysis
- Trend ClassFlat and Down
- Trend PowerAlmost flat
- PatternDescending Broadering Wedge
- EMA-20Bearish reversal2025-03-25 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-50Bearish reversal2025-03-24 the price crossed down the moving average line and demonstrates a downside trend.
- EMA-100Bearish reversal2025-03-10 the price crossed down the moving average line and demonstrates a strong downside trend.
- StochasticBullish weakeningThe stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.
- RSIBearish WeakeningRSI indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: exit from the overbought zone.
- MACDBearish WeakeningOscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: entry into the oversold zone.
- Candle pattern typeDojiIs formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | 0.36% | 4.11% | $21.93 | $22.14 | 59.74M |
| Week | 0.06% | 1.96% | $21.87 | $22.93 | 3.57B |
| Month | -15.64% | 0.15% | $20.92 | $26.52 | 19.94B |
| 3 Months | -16.86% | 5.36% | $20.92 | $27.24 | 52.15B |
| 6 Months | -23.48% | 19.73% | $20.92 | $29.22 | 100.82B |
| Year | -14.80% | 0.64% | $20.92 | $31.54 | 184.79B |
| 3 years | -54.91% | 56.01% | $20.92 | $54.93 | 553.17B |
| 5 years | -37.83% | 76.51% | $20.92 | $61.71 | 1.09T |
| All time | 15.63% | 54.85% | $11.62 | $61.71 | 1.06T |
Volatility
| PFE | By industry | |
|---|---|---|
| Yesterday | 23.54% | 1.03% |
| Week | 2.67% | 1.76% |
| Month | 8.80% | 9.54% |
| 3 Months | 13.07% | 20.61% |
| 6 Months | 16.56% | 29.79% |
| Year | 23.99% | 41.76% |
| 3 years | 41.55% | 90.20% |
| 5 years | 57.38% | 117.61% |
| All time | — | — |
- Sortino
- -0.42
- Sharpe
- -0.54
- Sterling
- -0.13
- Liquidity index
- 7.47
- Alpha
- -0.00081
- Beta
- 0.53
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$125.57B
Capitalization
5.67B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US7170811035
ISIN
1
Lot size
Dr. Albert Bourla D.V.M., DVM, Ph.D.
CEO
Website
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.